Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 9/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | DHFR | P00374 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15284246 | 0.89 | DCPS (0.62) | DCPSKCNH2DHFR | |
| SCHEMBL6484468 | 0.88 | DCPS (0.60) | DCPSKCNH2DHFR | |
| SCHEMBL6477195 | 0.86 | DCPS (0.63) | DCPSKCNH2DHFR | |
| SCHEMBL2125407 | 0.86 | DCPS (0.59) | DCPSKCNH2DHFR | |
| SCHEMBL15284402 | 0.86 | DCPS (0.59) | DCPSKCNH2DHFR | |
| SCHEMBL2128429 | 0.86 | DCPS (0.72) | DCPSKCNH2DHFR | |
| SCHEMBL2125359 | 0.85 | DCPS (0.76) | DCPSKCNH2DHFR | |
| SCHEMBL15293079 | 0.84 | LMNA (0.50) | DCPSKCNH2DHFR | |
| SCHEMBL2127066 | 0.84 | DCPS (0.56) | DCPSKCNH2DHFR | |
| SCHEMBL2125495 | 0.84 | DCPS (0.68) | DCPSKCNH2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133138-B2 | Use of a quinazoline compound in preparing a medicament against flaviviridae virus | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-09-15 | — | — | US | disclosed |
| US-9133138-B2 | Use of a quinazoline compound in preparing a medicament against flaviviridae virus | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-09-15 | — | — | US | disclosed |
| EP-2649999-A1 | USE OF QUINAZOLINE COMPOUND IN PREPARATION OF ANTI-FLAVIVIRUS DRUG | Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261139-A1 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-10-03 | — | — | US | disclosed |
| US-20130261139-A1 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-10-03 | — | — | US | disclosed |
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-6911446-B2 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | SUGEN, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| WO-2004113305-A2 | DIAMINO SUBSTITUTED QUINAZOLINE DERIVATIVES AS PROMOTERS OF SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | TANG PENG C (US) | 2001-08-16 | — | — | US | disclosed |
| US-6204267-B1 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | SUGEN, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0981519-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | Sugen, Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998050370-A1 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014679-A1 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds | RAF1, STK3, MKNK1 | DCPS 3645/4885KCNH2 4444/4885DHFR 1842/4885 |
| US-20130261139-A1 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS | EIF2AK2, GOT1, DDX5 | DCPS 587/4885KCNH2 2793/4885DHFR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.